{"id":637,"date":"2026-03-18T16:30:26","date_gmt":"2026-03-18T15:30:26","guid":{"rendered":"https:\/\/www.aescap.com\/?page_id=637"},"modified":"2026-06-30T09:10:45","modified_gmt":"2026-06-30T08:10:45","slug":"aescap-life-sciences-fonds","status":"publish","type":"page","link":"https:\/\/www.aescap.com\/nl\/aescap-life-sciences-fonds\/","title":{"rendered":"Aescap Life Sciences Fonds"},"content":{"rendered":"<div class=\"block\" id=\"Aescap-Life-Sciences-Fonds\">\n  <div class=\"block-inner\">\n    <div class=\"block-text\">\n              <span class=\"section-label\">beleggen in Aescap Life Sciences<\/span>\n                    <h2>Ondernemingen die de geneeskunde vooruitbrengen<\/h2>\n                    <p>Het Aescap Life Sciences Fonds bestaat sinds 28 maart 2016. Het is een open-end fonds waarbij u 2x per maand kunt in- en uitstappen. Het belegt in beursgenoteerde biotechbedrijven die de geneesmiddelen van de toekomst ontwikkelen en op de markt brengen.<\/p>\n<p>In de 10 jaar dat het fonds actief is heeft het aanzienlijk <a href=\"https:\/\/www.aescap.com\/nl\/rendement\/\">beter gepresteerd<\/a> dan haar benchmark, de iShares Biotech ETF in EUR. Het fonds draagt daarnaast bij aan de ontwikkeling van betere behandelingen voor ziekten met een aanzienlijke en nog onvervulde medische behoefte: van ALS en Alzheimer tot kanker, MS, Parkinson en talloze andere aandoeningen.<\/p>\n                      <\/div>\n    <div class=\"block-image\">\n      <img decoding=\"async\" src=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2026\/03\/medical-supplies-PD-1.jpeg\" alt=\"Ondernemingen die de geneeskunde vooruitbrengen\">\n      <div class=\"accent-line\"><\/div>\n    <\/div>\n  <\/div>\n<\/div>\n\n<script>\n(function() {\n  document.querySelectorAll('.show-more-toggle').forEach(function(btn) {\n    if (btn.dataset.bound) return;\n    btn.dataset.bound = '1';\n    btn.addEventListener('click', function() {\n      var content = this.nextElementSibling;\n      var isOpen = content.classList.contains('is-open');\n      content.classList.toggle('is-open');\n      this.setAttribute('aria-expanded', !isOpen);\n      this.querySelector('.show-more-chevron').textContent = isOpen ? '\\u25BE' : '\\u25B4';\n    });\n  });\n})();\n<\/script>\n\n\n<section class=\"section highlight-section\">\n  <div class=\"container highlight-content\">\n    <div class=\"reveal\">\n              <span class=\"section-label\" style=\"color: var(--light-blue);\">Fondsgegevens<\/span>\n                          <p>Het Aescap Life Sciences Fonds belegt in een geconcentreerd portfolio van circa 20 beursgenoteerde biotech- en life sciences bedrijven. Het fonds heeft sinds oprichting een aanzienlijke out-performance ten opzichte van haar benchmark, de iShares Biotech ETF (IBB) in EUR laten zien.<\/p>\n          <\/div>\n\n          <div class=\"stats-grid\">\n                              <div class=\"stat reveal reveal-delay-1\">\n              <div class=\"stat-number\">\u00b120<\/div>\n              <div class=\"stat-label\">Bedrijven in portfolio<\/div>\n            <\/div>\n                                        <div class=\"stat reveal reveal-delay-2\">\n              <div class=\"stat-number\">\u20ac142M<\/div>\n              <div class=\"stat-label\">AUM &#8211; Max. fundsize \u20ac500M<\/div>\n            <\/div>\n                                        <div class=\"stat reveal reveal-delay-3\">\n              <div class=\"stat-number\">+20%<\/div>\n              <div class=\"stat-label\">Rendementsdoelstelling netto per jaar op middellange termijn<\/div>\n            <\/div>\n                                        <div class=\"stat reveal reveal-delay-1\">\n              <div class=\"stat-number\">+32,5%<\/div>\n              <div class=\"stat-label\">Rendement in 2025<\/div>\n            <\/div>\n                                        <a href=\"https:\/\/www.aescap.com\/nl\/rendement\/\" class=\"stat stat-linked reveal reveal-delay-2\" >\n              <div class=\"stat-number\">+53%*<\/div>\n              <div class=\"stat-label\">Outperformance vs. IBB Benchmark (in EUR)<\/div>\n            <\/a>\n                                        <div class=\"stat reveal reveal-delay-3\">\n              <div class=\"stat-number\">+9,2%*<\/div>\n              <div class=\"stat-label\">Net IRR sinds maart 2016 (10-jaars data)<\/div>\n            <\/div>\n                                        <div class=\"stat reveal reveal-delay-1\">\n              <div class=\"stat-number\">1,44% | 17%**<\/div>\n              <div class=\"stat-label\">Management fee | Performance Fee<\/div>\n            <\/div>\n                                        <div class=\"stat reveal reveal-delay-2\">\n              <div class=\"stat-number\">0,0% | 0,2% <\/div>\n              <div class=\"stat-label\">Entry fee | Exit fee<\/div>\n            <\/div>\n                                        <div class=\"stat reveal reveal-delay-3\">\n              <div class=\"stat-number\">1,7%<\/div>\n              <div class=\"stat-label\">Total cost ratio (verwachting 2026)<\/div>\n            <\/div>\n                        <\/div>\n    \n          <div class=\"highlight-actions reveal reveal-delay-3\">\n                  <a href=\"https:\/\/www.aescap.com\/nl\/rendement\/\" class=\"btn-primary\" >\n            Volledig overzicht Performance &amp; NAV            <span class=\"arrow\">&rarr;<\/span>\n          <\/a>\n                      <\/div>\n    \n          <div class=\"reveal reveal-delay-3\" style=\"margin-top: 2.5rem;\">\n        <p style=\"font-size: 0.95rem; color: rgba(255, 255, 255, 0.5); max-width: 600px; line-height: 1.7;\">* Van de start van het fonds in 2016 tot 1-1-2026.\r\n** Bij bedragen boven 10M gelden lagere fees<\/p>\n      <\/div>\n      <\/div>\n<\/section>\n\n\n<section class=\"section\" id=\"LS-Beleggingsstrategie\" style=\"background: var(--off-white);\">\n  <div class=\"container\">\n    <div class=\"reveal\">\n              <span class=\"section-label\">Beleggingsstrategie<\/span>\n                    <h2 style=\"font-family: var(--font-heading); font-size: clamp(2rem, 3vw, 2.5rem); font-weight: 400; color: var(--dark-blue); margin-bottom: 1rem;\">Focus &amp; discipline<\/h2>\n                    <p style=\"font-size: 1.05rem; color: var(--gray-600); max-width: 600px; font-weight: 400; line-height: 1.8; margin-bottom: 1rem;\">Het Aescap Life Sciences Fonds wordt actief beheerd op basis van &#039;high conviction&#039;, op basis van uitgebreide fundamentele analyses gecombineerd met intensieve interactie met management en relevante experts.<\/p>\n          <\/div>\n          <div class=\"reasons-grid reasons-grid--cols-3\">\n                  <div class=\"reason-card reveal reveal-delay-1\">\n                          <div class=\"reason-icon blue\">\n                <svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\" stroke-linecap=\"round\"><line x1=\"18\" y1=\"20\" x2=\"18\" y2=\"10\"\/><line x1=\"12\" y1=\"20\" x2=\"12\" y2=\"4\"\/><line x1=\"6\" y1=\"20\" x2=\"6\" y2=\"14\"\/><\/svg>              <\/div>\n                        <h3>Groeipotentieel<\/h3>\n            <p>Selectie op basis van &#039;future earning power&#039;, sterk management en beperkt risico. Voorkeur voor bedrijven met geneesmiddelen op de markt \u00e9n een brede pijplijn met onderscheidende geneesmiddelkandidaten.<\/p>\n                      <\/div>\n                  <div class=\"reason-card reveal reveal-delay-2\">\n                          <div class=\"reason-icon blue\">\n                <svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\" stroke-linecap=\"round\"><circle cx=\"11\" cy=\"11\" r=\"8\"\/><path d=\"m21 21-4.35-4.35\"\/><path d=\"M11 8v6\"\/><path d=\"M8 11h6\"\/><\/svg>              <\/div>\n                        <h3>Technologieplatforms<\/h3>\n            <p>Voorkeur voor bedrijven met een technologieplatform dat meerdere ziektegebieden kan adresseren en een deel daarvan uit-licenseert t.b.v. extra inkomsten via mijlpaalbetalingen en royalty&#039;s.<\/p>\n                      <\/div>\n                  <div class=\"reason-card reveal reveal-delay-3\">\n                          <div class=\"reason-icon blue\">\n                <svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\" stroke-linecap=\"round\"><path d=\"M20 21v-2a4 4 0 0 0-4-4H8a4 4 0 0 0-4 4v2\"\/><circle cx=\"12\" cy=\"7\" r=\"4\"\/><\/svg>              <\/div>\n                        <h3>Discipline<\/h3>\n            <p>Discipline in de aan- en verkoop van aandelen in een onderneming, op basis van een koop bij significante onderwaardering en een verkoop wanneer de koers richting ons koersdoel gaat. Zo voorkomen we dat we mee gaan in een bubbel. De volatiliteit van biotechaandelen cre\u00ebert buy-low\/sell-high kansen voor een ervaren fondsbeheerder.<\/p>\n                      <\/div>\n                  <div class=\"reason-card reveal reveal-delay-1\">\n                          <div class=\"reason-icon blue\">\n                <svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\" stroke-linecap=\"round\"><path d=\"M12 22s8-4 8-10V5l-8-3-8 3v7c0 6 8 10 8 10z\"\/><\/svg>              <\/div>\n                        <h3>Diversificatie &amp; Risicobeheer<\/h3>\n            <p>Gebalanceerd portfolio, gediversifieerd over ziektegebieden, technologie\u00ebn, geografie\u00ebn en ontwikkelfases. Max. 25% van AUM in high risk \/ high return posities. Rebalancing op basis van target price versus actuele koers.<\/p>\n                      <\/div>\n                  <div class=\"reason-card reveal reveal-delay-2\">\n                          <div class=\"reason-icon blue\">\n                <svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\" stroke-linecap=\"round\"><path d=\"M22 11.08V12a10 10 0 1 1-5.93-9.14\"\/><polyline points=\"22 4 12 14.01 9 11.01\"\/><\/svg>              <\/div>\n                        <h3>DCF-waardering<\/h3>\n            <p>Wij berekenen, speculeren niet. Elke onderneming wordt gewaardeerd op basis van discounted cash flow-analyse en proprietary field research.<\/p>\n                      <\/div>\n                  <div class=\"reason-card reason-card--dark reveal reveal-delay-3\">\n                          <div class=\"reason-icon blue\">\n                <svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"1.5\" stroke-linecap=\"round\"><path d=\"M4 4h16c1.1 0 2 .9 2 2v12c0 1.1-.9 2-2 2H4c-1.1 0-2-.9-2-2V6c0-1.1.9-2 2-2z\"\/><polyline points=\"22,6 12,13 2,6\"\/><\/svg>              <\/div>\n                        <h3>Meer weten over onze strategie?<\/h3>\n            <p>In een gesprek komt u direct alles te weten over de strategie van het fonds<\/p>\n                          <a href=\"mailto:service@aescap.com?subject=Ik%20kom%20graag%20meer%20te%20weten%20over%20de%20beleggingsstrategie%20van%20Aescap%20Life%20Sciences\" class=\"block-link\" target=\"_blank\">\n                Stuur een mail aan ons team                <span>&rarr;<\/span>\n              <\/a>\n                      <\/div>\n              <\/div>\n      <\/div>\n<\/section>\n\n\n<section class=\"section\" id=\"LS-Beleggingsstrategie\" style=\"background: var(--off-white);\">\n  <div class=\"container\">\n    <div class=\"reveal\">\n              <span class=\"section-label\">Competitive edge<\/span>\n                    <h2 style=\"font-family: var(--font-heading); font-size: clamp(2rem, 3vw, 2.5rem); font-weight: 400; color: var(--dark-blue); margin-bottom: 1rem;\">Wat ons onderscheidt<\/h2>\n          <\/div>\n          <div class=\"vacatures-grid\">\n                  <div class=\"vacature-card reveal reveal-delay-1\">\n            <h4>Clinical trial expertise<\/h4>\n            <p>Zeer ervaren in het beoordelen van klinische data en het vertalen naar marktpotentieel.<\/p>\n                      <\/div>\n                  <div class=\"vacature-card reveal reveal-delay-2\">\n            <h4>AI &amp; Data Science<\/h4>\n            <p>Dedicated team van AI-engineers dat data-gedreven inzichten levert voor investeringsbeslissingen.<\/p>\n                      <\/div>\n                  <div class=\"vacature-card reveal reveal-delay-3\">\n            <h4>Management dialogue<\/h4>\n            <p>In constant dialoog met het management van portfoliobedrijven: private equity-mentaliteit in publieke markten.<\/p>\n                      <\/div>\n                  <div class=\"vacature-card reveal reveal-delay-4\">\n            <h4>Skin in the game<\/h4>\n            <p>Het Aescap investment team heeft meer dan \u20ac30 miljoen in het fonds ge\u00efnvesteerd.<\/p>\n                      <\/div>\n                  <div class=\"vacature-card reveal reveal-delay-1\">\n            <h4>Volatiliteit als kans<\/h4>\n            <p>Lage correlatie en hoge volatiliteit van biotechaandelen cre\u00ebren ideale buy-low\/sell-high mogelijkheden.<\/p>\n                      <\/div>\n                  <div class=\"vacature-card reveal reveal-delay-2\">\n            <h4>Medisch netwerk<\/h4>\n            <p>Toegang tot artsen, zorgverzekeraars, pati\u00ebnten en ervaren portfolio advisors voor medisch-wetenschappelijke diepgang.<\/p>\n                      <\/div>\n              <\/div>\n      <\/div>\n<\/section>\n\n\n\n<div class=\"block reverse\">\n  <div class=\"block-inner\">\n    <div class=\"block-text\">\n              <span class=\"section-label\">Risico&#039;s<\/span>\n                          <h2>Risico\u2019s<\/h2>\n<p>Om de beleggingsrisico\u2019s tot een minimum te beperken, spreidt het fonds zijn portefeuille over verschillende ziekten, verschillende stadia van bedrijfsontwikkeling en verschillende geografische gebieden. Het fonds identificeert een aantal risico\u2019s voor beleggers:<\/p>\n<ul>\n<li><strong>Liquiditeitsrisico<\/strong>: het kan voorkomen dat een door een ingenomen positie niet tijdig tegen een redelijke prijs kan worden geliquideerd vanwege gebrek aan liquiditeit (onvoldoende vraag) in de markt.<\/li>\n<li><strong>Sectorrisico<\/strong>: het fonds investeert in een sector die gekenmerkt wordt door een hoge beweeglijkheid waarbij een actieve beleggingsaanpak zeer belangrijk is. Dit kan een positieve of negatieve impact hebben op de waarde van het fonds.<\/li>\n<li><strong>Valutarisico<\/strong>: het fonds dekt valutaposities in beginsel niet af. Beleggingen anders dan in euro\u2019s kunnen hierdoor fluctuaties in de netto vermogenswaarde van het fonds, zowel positief als negatief, veroorzaken.<\/li>\n<\/ul>\n<p>Voor het overzicht van ge\u00efdentificeerde risico\u2019s verwijzen we naar de\u00a0<a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/01\/AescapLS_PROSP_EN.pdf\" target=\"_blank\" rel=\"noopener\">prospectus die u hier kunt downloaden.<\/a><\/p>\n                      <\/div>\n    <div class=\"block-image\">\n      <img decoding=\"async\" src=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2026\/03\/AFM-risico-icoon_6_NL.png\" alt=\"\">\n      <div class=\"accent-line\"><\/div>\n    <\/div>\n  <\/div>\n<\/div>\n\n<script>\n(function() {\n  document.querySelectorAll('.show-more-toggle').forEach(function(btn) {\n    if (btn.dataset.bound) return;\n    btn.dataset.bound = '1';\n    btn.addEventListener('click', function() {\n      var content = this.nextElementSibling;\n      var isOpen = content.classList.contains('is-open');\n      content.classList.toggle('is-open');\n      this.setAttribute('aria-expanded', !isOpen);\n      this.querySelector('.show-more-chevron').textContent = isOpen ? '\\u25BE' : '\\u25B4';\n    });\n  });\n})();\n<\/script>\n\n\n<div class=\"block\">\n  <div class=\"block-inner\">\n    <div class=\"block-text\">\n              <span class=\"section-label\">Vertrouwd<\/span>\n                    <h2>Governance &amp; Toezicht<\/h2>\n                    <p class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\">De beheerder van de fondsen, Privium Fund Management BV, staat onder toezicht van de AFM en DNB en werkt uitsluitend samen met onafhankelijke, gespecialiseerde partijen voor bewaring en administratie.<\/p>\n<ul class=\"[li_&amp;]:mb-0 [li_&amp;]:mt-1 [li_&amp;]:gap-1 [&amp;:not(:last-child)_ul]:pb-1 [&amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\">\n<li class=\"whitespace-normal break-words pl-2\"><strong>Bewaarder:<\/strong> Apex Depositary Services \u2014 verantwoordelijk voor de onafhankelijke bewaring van de fondsactiva.<\/li>\n<li class=\"whitespace-normal break-words pl-2\"><strong>Administrateur:<\/strong> IQEQ Financial Services \u2014 verantwoordelijk voor de onafhankelijke fondadministratie en NAV-berekening.<\/li>\n<li><strong>Accountant:<\/strong> Forvis Mazars N.V. \u2014 verantwoordelijk voor de onafhankelijke controle van de jaarrekening.<\/li>\n<\/ul>\n                      <\/div>\n    <div class=\"block-image\">\n      <img decoding=\"async\" src=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2026\/04\/Parties-involved-2-scaled.png\" alt=\"Governance &amp; Toezicht\">\n      <div class=\"accent-line\"><\/div>\n    <\/div>\n  <\/div>\n<\/div>\n\n<script>\n(function() {\n  document.querySelectorAll('.show-more-toggle').forEach(function(btn) {\n    if (btn.dataset.bound) return;\n    btn.dataset.bound = '1';\n    btn.addEventListener('click', function() {\n      var content = this.nextElementSibling;\n      var isOpen = content.classList.contains('is-open');\n      content.classList.toggle('is-open');\n      this.setAttribute('aria-expanded', !isOpen);\n      this.querySelector('.show-more-chevron').textContent = isOpen ? '\\u25BE' : '\\u25B4';\n    });\n  });\n})();\n<\/script>\n\n\n<div class=\"block reverse\" id=\"LS-Duurzaamheid\">\n  <div class=\"block-inner\">\n    <div class=\"block-text\">\n              <span class=\"section-label\">Samenvatting Aescap Life Sciences<\/span>\n                    <h2>Duurzaamheidsgerelateerde informatie en disclosures<\/h2>\n                    <p>Aescap Life Sciences (het\u00a0<strong>Fonds<\/strong>) heeft als doel waarde te cre\u00ebren door te beleggen in beursgenoteerde aandelen van biotechnologische ondernemingen en mogelijk ook in ondernemingen op het gebied van diagnostiek en\/of medische apparatuur. Het Fonds streeft naar een gemiddeld jaarlijks nettorendement (na aftrek van kosten) van 20 procent over 4-5 jaar. Het Fonds zal doorgaans investeren in bedrijven die het potentieel hebben om hun aandelenprijs over deze periode (meer dan) te verdubbelen.<\/p>\n                    <button class=\"show-more-toggle\" type=\"button\" aria-expanded=\"false\">\n          Lees meer          <span class=\"show-more-chevron\">&#9662;<\/span>\n        <\/button>\n        <div class=\"show-more-content\">\n          <p>Naast het doel om een financieel rendement voor investeerders te behalen, bevordert het Fonds ook een sociaal kenmerk en is derhalve geclassificeerd onder artikel 8 van de\u00a0<em>Sustainable Finance Disclosure Regulation<\/em>\u00a0(<strong>SFDR<\/strong>). De investeringen van het Fonds zijn voornamelijk gericht op het onderzoek naar, de ontwikkeling van of de productie van behandelingen\/oplossingen voor ziekten met een hoge onvervulde medische behoefte. Een hoge onvervulde medische behoefte is gedefinieerd als ziekten die worden gekenmerkt door een (ontoereikendheid van) beschikbare behandelingen, die ernstige gevolgen hebben voor de pati\u00ebnt en het zorgsysteem, en die voorkomen in de regio\u2019s waar de onderneming momenteel de huidige of toekomstige product(en) op de markt brengt of van plan is te gaan distribueren. Het Fonds streeft ernaar een portefeuille samen te stellen van ongeveer twintig ondernemingen die bijdragen aan het sociale kenmerk, en waarvan minimaal 30 procent (van het belegd vermogen van het Fonds) als duurzaam wordt beschouwd. Het belegd vermogen bestaat uit het Fondsvermogen, exclusief liquide middelen. Naast het vaststellen van de duurzaamheidsrisico\u2019s voor iedere investering die materieel worden beschouwd op basis van de\u00a0<em>Sustainability Accounting Standards Board<\/em>\u00a0(<strong>SASB<\/strong>), analyseert het Fonds als onderdeel van het due diligence proces ook de mate waarin de onderneming op deze duurzaamheidsrisico\u2019s is voorbereid. Het Fonds houdt rekening met de\u00a0<em>Principal Adverse Impact<\/em>\u00a0(<strong>PAI<\/strong>) indicatoren om te bepalen of een belegging als duurzaam kan worden beschouwd. Het Fonds onderzoekt de processen en het beleid van iedere (potenti\u00eble) investering op ecologische en sociale risico\u2019s zoals gedefinieerd door de SASB voor de biotechnologie en farmaceutische sector en door de PAI indicatoren. Het monitoren van investeringen met betrekking tot hun prestaties op ecologisch, sociaal en goed bestuur gebied (<em>Environmental, Social and Governance<\/em>,\u00a0<strong>ESG<\/strong>) vindt maandelijks plaats. Maandelijks wordt er gerapporteerd op de materiele duurzaamheidsrisico\u2019s, het aandeel investeringen van het belegd vermogen dat bijdraagt aan het sociale kenmerk en het aandeel investeringen dat als duurzaam is aangemerkt. Het Fonds benadert de investeringen om hun ESG-prestaties te verbeteren door middel van zogeheten engagement. Engagement kan bestaan uit overleggen met het management, gegevens verzoeken aan een Investor Relations afdeling, sturing om beleid en de praktijken binnen ondernemingen te verbeteren, of formeel stemmen als aandeelhouder wanneer dat nodig wordt geacht. Het Fonds rapporteert maandelijks en kwartaallijks over haar financi\u00eble resultaten. Ook publiceert het Fonds jaarlijks een PAI-verslag waarin de engagement activiteiten worden belicht.<\/p>\n<ul>\n<li><a href=\"https:\/\/www.aescap.com\/aescap-life-sciences-fund\/#LS-Sustainability-related-Disclosures\">Summary<\/a> (EN)<\/li>\n<li><a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/12\/AescapLS_SFDR_Summary_DK.pdf\" target=\"_blank\" rel=\"noopener\">Sammenfatning<\/a>\u00a0(DK)<\/li>\n<\/ul>\n        <\/div>\n                    <a href=\"https:\/\/www.aescap.com\/nl\/environmental-social-governance-esg\/\" class=\"block-link\" >\n          Duurzaamheidsinformatie &amp; disclosures          <span>&rarr;<\/span>\n        <\/a>\n          <\/div>\n    <div class=\"block-image\">\n      <img decoding=\"async\" src=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2026\/03\/Duurzaam-blauw-scaled.png\" alt=\"Duurzaamheidsgerelateerde informatie en disclosures\">\n      <div class=\"accent-line\"><\/div>\n    <\/div>\n  <\/div>\n<\/div>\n\n<script>\n(function() {\n  document.querySelectorAll('.show-more-toggle').forEach(function(btn) {\n    if (btn.dataset.bound) return;\n    btn.dataset.bound = '1';\n    btn.addEventListener('click', function() {\n      var content = this.nextElementSibling;\n      var isOpen = content.classList.contains('is-open');\n      content.classList.toggle('is-open');\n      this.setAttribute('aria-expanded', !isOpen);\n      this.querySelector('.show-more-chevron').textContent = isOpen ? '\\u25BE' : '\\u25B4';\n    });\n  });\n})();\n<\/script>\n\n\n<section class=\"section\" id=\"documenten\">\n  <div class=\"container\">\n    <div class=\"reveal\">\n              <span class=\"section-label\">Documenten<\/span>\n                    <h2 style=\"font-family: var(--font-heading); font-size: clamp(2rem, 3vw, 2.5rem); font-weight: 400; color: var(--dark-blue); margin-bottom: 1rem;\">Aescap Life Sciences Fondsdocumenten<\/h2>\n                    <p style=\"font-size: 1.05rem; color: var(--gray-600); max-width: 700px; font-weight: 400; line-height: 1.8; margin-bottom: 1rem;\">Download de relevante fondsdocumenten van Aescap Life Sciences. Neem contact met ons op als u aanvullende informatie wenst.<\/p>\n          <\/div>\n\n          <div class=\"docs-grid\">\n                  <div class=\"docs-column reveal reveal-delay-1\">\n            <h3>Prospectus<\/h3>\n                          <ul>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/01\/AescapLS_PROSP_EN.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Prospectus Aescap Life Sciences                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2023\/08\/AescapLS_SUPPL1_PROSP_EN.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Supplement I to Prospectus Aescap Life Sciences                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2023\/08\/AescapLS_EXPL_SUPPL1_PROSP_EN.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Explanation regarding Supplement I to Prospectus Aescap Life Sciences                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2023\/10\/AescapLS_SUPPL2_PROSP_EN.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Supplement II to Prospectus Aescap Life Sciences                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2023\/11\/AescapLS_EXPL_SUPPL2_PROSP_EN.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Explanation regarding Supplement II to Prospectus Aescap Life Sciences                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/12\/AescapLS_SFDR_PCD_EN.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      SFDR Pre-contractual disclosure document Aescap Life Sciences (version 2.3, August 2024)                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/12\/AescapLS_SFDR_PAI_Statement_EN.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      PAI Report 2024 Aescap Life Sciences                    <\/a>\n                  <\/li>\n                              <\/ul>\n                      <\/div>\n                  <div class=\"docs-column reveal reveal-delay-2\">\n            <h3>Essenti\u00eble-informatiedocumenten<\/h3>\n                          <ul>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/02\/AescapLS_Manager_KID_NL.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      KID Unit Class Aescap Life Sciences \u2013 Manager                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/02\/AescapLS_Investors_KID_NL.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      KID Unit Class Aescap Life Sciences \u2013 Investors                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2023\/08\/AescapLS_Investors-Allfunds_KID_NL.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      KID Unit Class Aescap Life Sciences \u2013 Investors Allfunds                     <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/02\/AescapLS_Investors-500k_KID_NL.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      KID Unit Class Aescap Life Sciences \u2013 Investors &lt; 500k                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/02\/AescapLS_Investor-10M_KID_NL.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      KID Unit Class Aescap Life Sciences \u2013 Investors 10M+                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/02\/AescapLS_Investor-20M_KID_NL.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      KID Unit Class Aescap Life Sciences \u2013 Investors 20M+                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/02\/AescapLS_Investor-30M_KID_NL.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      KID Unit Class Aescap Life Sciences \u2013 Investors 30M+                    <\/a>\n                  <\/li>\n                              <\/ul>\n                      <\/div>\n                  <div class=\"docs-column reveal reveal-delay-3\">\n            <h3>Formulieren<\/h3>\n                          <ul>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/06\/AescapLS_SUBFORM_EN.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Subscription form Aescap Life Sciences                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/06\/AescapLS_ADDL_SUBFORM_EN.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Additional Subscription form Aescap Life Sciences                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2019\/02\/190130-FATCA_CRS-individuals.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      FATCA formulier &#8211; Self-certification form (individuals)                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2019\/02\/190130-FATCA_CRS-Entities.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      FATCA formulier &#8211; Self-certification form (entities)                    <\/a>\n                  <\/li>\n                              <\/ul>\n                      <\/div>\n                  <div class=\"docs-column reveal reveal-delay-1\">\n            <h3>Financial Reports Aescap Life Sciences<\/h3>\n                          <ul>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/05\/AescapLS_ARPT_EN.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Annual Report 2025 Aescap Life Sciences                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/01\/AescapLS_SARPT_EN.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Semi-Annual Report 2025 Aescap Life Sciences                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2026\/04\/250429-Annual-Report-2024-Aescap-Life-Sciences.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Annual Report 2024 Aescap Life Sciences                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2024\/08\/AESCAP-Life-Sciences_Semi-Annual-report.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Semi-Annual Report 2024 Aescap Life Sciences                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2025\/04\/240430-Annual-Report-Aescap-Life-Sciences.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Annual Report 2023 Aescap Life Sciences                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2023\/09\/230817-Interim-Financial-Statements-2023-Aescap-Life-Sciences.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Semi-Annual Report 2023 Aescap Life Sciences                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2024\/04\/230430-Annual-Report-2022-Aescap-Life-Sciences.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Annual Report 2022 Aescap Life Sciences                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2022\/09\/220801-Interim-Financial-Statements-2022-Aescap-Life-Sciences.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Semi-Annual Report 2022 Aescap Life Sciences                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2022\/05\/220422-Annual-Report-2021-Aescap-Life-Sciences.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Annual Report 2021 Aescap Life Sciences                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2021\/09\/210730-Interim-Financial-Statements-2021-Aescap-Life-Sciences.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Semi-Annual Report 2021 Aescap Life Sciences                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2021\/05\/Annual-report-2020-Aescap-Life-Sciences.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Annual Report 2020 Aescap Life Sciences                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2020\/09\/2020-Interim-report-Aescap.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Semi-Annual Report 2020 Aescap Life Sciences                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2020\/09\/2019-Annual-report-Aescap.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Annual Report 2019 Aescap Life Sciences                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2020\/09\/2019-Interim-report-Aescap.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Semi-Annual Report 2019 Aescap Life Sciences                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2020\/09\/2018-Annual-report-Aescap.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Annual Report 2018 Aescap Life Sciences                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.aescap.com\/wp-content\/uploads\/2020\/09\/2017-Annual-report-Aescap-extended-bookyear.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Annual Report 2017\/2016 (Extended Bookyear) Aescap Life Sciences                    <\/a>\n                  <\/li>\n                              <\/ul>\n                      <\/div>\n                  <div class=\"docs-column reveal reveal-delay-2\">\n            <h3>Fund Manager &#8211; Privium Fund Management<\/h3>\n                          <ul>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/05\/PFM_BV_ChamberofCommerce.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Extract Chamber of Commerce                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"#\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Copy of Investment Management licence                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"#\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Confirmation Privium FM Status AIFM                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/05\/PFM_BV_Remuneration_Policy.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Remuneration Policy Privium Fund Management B.V.                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/05\/PFM_BV_Statement_Regarding_Principal_Adverse_Impacts.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Statement regarding Principal Adverse Impacts                    <\/a>\n                  <\/li>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/wp-content\/uploads\/2022\/05\/PFM_BV_Integration_of_sustainability_risks.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      Integration of sustainability risks                    <\/a>\n                  <\/li>\n                              <\/ul>\n                      <\/div>\n                  <div class=\"docs-column reveal reveal-delay-3\">\n            <h3>Financial Reports Fund Manager<\/h3>\n                          <ul>\n                                  <li>\n                    <a href=\"https:\/\/www.priviumfund.com\/privium-amsterdam\/\" target=\"_blank\" rel=\"noopener noreferrer\">\n                      <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M14 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V8z\"\/><polyline points=\"14 2 14 8 20 8\"\/><\/svg>                      (Semi) Annual Financial Reports via website van Privium Fund Management BV                    <\/a>\n                  <\/li>\n                              <\/ul>\n                      <\/div>\n              <\/div>\n      <\/div>\n<\/section>\n\n\n<section class=\"section cta-section\">\n  <div class=\"container cta-content\">\n    <div class=\"reveal\">\n              <h2>Klaar om te investeren in de toekomst van gezondheidszorg?<\/h2>\n                    <p>Neem contact op voor een persoonlijk gesprek of schrijf u in voor onze nieuwsbrief.<\/p>\n          <\/div>\n    <div class=\"cta-actions reveal reveal-delay-1\">\n              <a href=\"https:\/\/aescap.pipedrive.com\/scheduler\/wOYYEktD\/intro-meeting-aescap\" class=\"btn-primary\" target=\"_blank\">\n          Plan een kennismaking          <span class=\"arrow\">&rarr;<\/span>\n        <\/a>\n                    <a href=\"#\" class=\"btn-cta-outline\" >\n          <svg width=\"16\" height=\"16\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\"><path d=\"M4 4h16c1.1 0 2 .9 2 2v12c0 1.1-.9 2-2 2H4c-1.1 0-2-.9-2-2V6c0-1.1.9-2 2-2z\"\/><polyline points=\"22,6 12,13 2,6\"\/><\/svg>\n          Schrijf in voor nieuwsbrief        <\/a>\n          <\/div>\n  <\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-637","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aescap Life Sciences Fonds - Aescap<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.aescap.com\/nl\/aescap-life-sciences-fonds\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aescap Life Sciences Fonds - Aescap\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.aescap.com\/nl\/aescap-life-sciences-fonds\/\" \/>\n<meta property=\"og:site_name\" content=\"Aescap\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-30T08:10:45+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.aescap.com\\\/nl\\\/aescap-life-sciences-fonds\\\/\",\"url\":\"https:\\\/\\\/www.aescap.com\\\/nl\\\/aescap-life-sciences-fonds\\\/\",\"name\":\"Aescap Life Sciences Fonds - Aescap\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.aescap.com\\\/#website\"},\"datePublished\":\"2026-03-18T15:30:26+00:00\",\"dateModified\":\"2026-06-30T08:10:45+00:00\",\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.aescap.com\\\/nl\\\/aescap-life-sciences-fonds\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.aescap.com\\\/#website\",\"url\":\"https:\\\/\\\/www.aescap.com\\\/\",\"name\":\"Aescap\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.aescap.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.aescap.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.aescap.com\\\/#organization\",\"name\":\"Aescap\",\"url\":\"https:\\\/\\\/www.aescap.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/www.aescap.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.aescap.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/cropped-logo2021_restyle_180.png\",\"contentUrl\":\"https:\\\/\\\/www.aescap.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/cropped-logo2021_restyle_180.png\",\"width\":180,\"height\":121,\"caption\":\"Aescap\"},\"image\":{\"@id\":\"https:\\\/\\\/www.aescap.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aescap Life Sciences Fonds - Aescap","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.aescap.com\/nl\/aescap-life-sciences-fonds\/","og_locale":"nl_NL","og_type":"article","og_title":"Aescap Life Sciences Fonds - Aescap","og_url":"https:\/\/www.aescap.com\/nl\/aescap-life-sciences-fonds\/","og_site_name":"Aescap","article_modified_time":"2026-06-30T08:10:45+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.aescap.com\/nl\/aescap-life-sciences-fonds\/","url":"https:\/\/www.aescap.com\/nl\/aescap-life-sciences-fonds\/","name":"Aescap Life Sciences Fonds - Aescap","isPartOf":{"@id":"https:\/\/www.aescap.com\/#website"},"datePublished":"2026-03-18T15:30:26+00:00","dateModified":"2026-06-30T08:10:45+00:00","inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.aescap.com\/nl\/aescap-life-sciences-fonds\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.aescap.com\/#website","url":"https:\/\/www.aescap.com\/","name":"Aescap","description":"","publisher":{"@id":"https:\/\/www.aescap.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.aescap.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/www.aescap.com\/#organization","name":"Aescap","url":"https:\/\/www.aescap.com\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.aescap.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.aescap.com\/wp-content\/uploads\/2026\/02\/cropped-logo2021_restyle_180.png","contentUrl":"https:\/\/www.aescap.com\/wp-content\/uploads\/2026\/02\/cropped-logo2021_restyle_180.png","width":180,"height":121,"caption":"Aescap"},"image":{"@id":"https:\/\/www.aescap.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.aescap.com\/nl\/wp-json\/wp\/v2\/pages\/637","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.aescap.com\/nl\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.aescap.com\/nl\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.aescap.com\/nl\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.aescap.com\/nl\/wp-json\/wp\/v2\/comments?post=637"}],"version-history":[{"count":121,"href":"https:\/\/www.aescap.com\/nl\/wp-json\/wp\/v2\/pages\/637\/revisions"}],"predecessor-version":[{"id":1714,"href":"https:\/\/www.aescap.com\/nl\/wp-json\/wp\/v2\/pages\/637\/revisions\/1714"}],"wp:attachment":[{"href":"https:\/\/www.aescap.com\/nl\/wp-json\/wp\/v2\/media?parent=637"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}